nucleic acid detection

The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.

The agency updated its guidance for samples tested using nucleic acid testing, saying the technology has improved detection for the viruses.

The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.